The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial (Q102212198)
Jump to navigation
Jump to search
scientific article published on 20 November 2020
Language | Label | Description | Also known as |
---|---|---|---|
English | The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial |
scientific article published on 20 November 2020 |
Statements
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial (English)
John G F Cleland
João Pedro Ferreira
Beatrice Mariottoni
Pierpaolo Pellicori
Joe Cuthbert
Job A J Verdonschot
Johannes Petutschnigg
Fozia Z Ahmed
Franco Cosmi
Hans-Peter Brunner La Rocca
Mamas A Mamas
Andrew L Clark
Frank Edelmann
Burkert Pieske
Javed Khan
Ken McDonald
Philippe Rouet
Jan A Staessen
Blerim Mujaj
Arantxa González
Javier Diez
Mark Hazebroek
Stephane Heymans
Roberto Latini
Stéphanie Grojean
Anne Pizard
Nicolas Girerd
Patrick Rossignol
Tim J Collier
Faiez Zannad
20 November 2020
20 November 2020
1 reference